2014, Number 1
Three “Magic Bullets”. Which One to Choose? About the Initial Treatment of Chronic Granulocytic Leukemia
PDF size: 247.63 Kb.
Text ExtractionNo abstract
Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology, ASH Education Program, 2013:168-175.
Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42
Ruiz-Argüelles GJ, Tarin-Arzaga LC, González-Carrillo ML, et al Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? Bone Marrow Transplant 2008;42:23-28.